Laminar Pharmaceuticals
Manufacturing · Spain · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Ctra Valldemossa Mód c-8 Km. 7,4 Parcbit...Phone Number
(978) 631-0600Website
www.laminarpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Laminar Pharmaceuticals
Laminar Pharma is a pioneering biopharmaceutical company dedicated to the discovery, design, and initial clinical development of next-generation medicines. The company specializes in a novel therapeutic approach known as melitherapy, focusing on first-in-class molecules that target membrane lipids. Laminar Pharma aims to provide reference treatments for diseases with unmet medical needs, including cancer and Alzheimer's disease. Their innovative pipeline includes products like LAM561, LAM226, and LAM204, which are currently undergoing clinical trials.Explore more
Laminar Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Laminar Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Laminar Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Laminar Pharmaceuticals
Funding: Get notified immidiatlly once Laminar Pharmaceuticals has new funding data
Website visits: Recent activity has been detected on your website
Laminar Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Laminar Pharmaceuticals recently announced quarterly report
Click to see if Laminar Pharmaceuticals had a recent Job posting/layoffs
Check out if Laminar Pharmaceuticals is spiking on competitors!
Product Launch: Get notified when Laminar Pharmaceuticals launches new products
Recommended Actions
Find VP level buyers at Laminar Pharmaceuticals
Find 2 more new buyers
Compare Similar Companies to Laminar Pharmaceuticals
Compare insights from companies similar to Laminar Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Laminar Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Laminar Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Laminar Pharmaceuticals.
Laminar Pharmaceuticals Tech Stack
A closer look at the technologies used by Laminar Pharmaceuticals
See more technologies
Laminar Pharmaceuticals News & Media
Laminar Pharma Raises 5.9M in a New Round of Financing - Born2Invest
Laminar Pharma raised €5.9 million, led by the Matutes family, for its growth and launch of anti-tumor drug LAM 561, aimed at glioblastoma treatment. Additional investors included the Alba Pérez Foundation and Dentol Capital. The company expects €1 billion in revenue by 2026, in collaboration with an undisclosed major pharmaceutical partner.Last patient in: Laminar Pharmaceuticals S.A. completes recruitment for CLINGLIO, the phase 2b/3 Clinical Trial of idroxioleic acid (LAM561) in combination with RT and TMZ for adults with newly diagnosed glioblastoma
140 patients have been recruited at sites in Spain, Italy, France and United Kingdom. The open readout of the trial is expected by late 2024. Laminar aims to submit regulatory filings or conditional marketing authorization by early 2025. PALMA DE MALLORCA, Spain, June 11, 2024...Laminar Pharmaceuticals S.A. receives recommendation from the Independent Data Monitoring Committee to advance to the next stage of CLINGLIO, the phase 2b/3 Clinical Trial of LAM561 in combination with RT and TMZ for adults with newly diagnosed glioblastoma
The independent data monitoring committee (IDMC) has recommended continuation of CLINGLIO without modification after its assessment of LAM561 interim efficacy in newly diagnosed Glioblastoma. This follows the previous recommendation in relation to safety. CLINGLIO remains on track to have...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Laminar Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Laminar Pharma is a pioneering biopharmaceutical company dedicated to the discovery, design, and initial clinical development of next-generation medicines. The company specializes in a novel therapeutic approach known as melitherapy, focusing on first-in-class molecules that target membrane lipids. Laminar Pharma aims to provide reference treatment... Read More
